Pertuzumab has clinical benefits in metastatic breast cancer but is not cost-effective
1. The incremental cost-effectiveness ratio of the pertuzumab group was $436,679 per QALY gained....
Read More
Oncology
Biosimilar HD201 has equivalent efficacy to trastuzumab in the treatment of ERBB2-positive (HER2) breast cancer
1. Total pathological complete response was not significantly different between trastuzumab and...
Read More
Liver Cancer: Support for the 3rd Leading Cancer-Related Cause of Death
Liver cancer is the third-highest cause of cancer-related deaths worldwide, and incidence of...
Read More
Cancer-Associated Thrombosis: A Look at Racial Disparities
When compared with the general population, patients with cancer-associated thrombosis (CAT) have...
Read More
Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: A Nomogram Predicting Overall Survival Benefit
For a study, the researchers sought to create and evaluate a nomogram that could predict overall...
Read More
Compared With Younger Patients, Octogenarians Have a Higher Quality Of Life After Lung Resection
For a study, the researchers sought to compare patients aged less than 80 to patients aged more...
Read More
Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases: Treatment Patterns
Whole-brain radiotherapy (WBRT) had been the standard of care for brain metastases (BMs) from...
Read More
In Elderly Patients With Stage III Non-Small Cell Lung Cancer, Concurrent vs Sequential Chemoradiotherapy Has a Better Outcome
Lung cancer was the most common cancer-related death in the world. Non-small cell lung cancer was...
Read More
In Thymic Epithelial Tumours and Small Cell Lung Cancer, Arginase Pathway Markers of Immune-Microenvironment
Arginase-1 and the adenosine pathway, which were major regulators of antitumor immunity, might...
Read More
Lung Cancer Risk Factors in an Underserved Safety-Net Screening Cohort
To identify patients for lung cancer screening, the USPSTF (the United States Preventive Services...
Read More
As a Surrogate For Tumour Tissue, Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer Revealed Additional Clinical Actionable Information.
In advanced lung cancer patients, pleural effusion (PE) was proven to be a promising source of...
Read More
Overall Survival Benefit of Adding Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumour Proportion Score of more than or equal to 50% Predicted by dNLR-Based Score
Pembrolizumab (P) was a common first-line therapeutic option for advanced non-small cell lung...
Read More
Increased Disparities in Patients Diagnosed with Metastatic Lung Cancer in the United States Following Lung CT Screening
For a study, the researchers sought to find if the introduction of low-dose computed tomography...
Read More
A Multi-Centre Retrospective Analysis of VATS vs Open Lobectomy in Pathological T1 SCLC
VATS, or video-assisted thoracic surgery, was widely employed in the surgical treatment of...
Read More
Second-line tisagenlecleucel does not improve outcomes in B-cell lymphoma
1. Patients with B-cell non-Hodgkin’s lymphoma receiving tisagenlecleucel did not show...
Read More
S-1 plus oxaliplatin noninferior to fluorouracil, leucovorin, and oxaliplatin in perioperative chemotherapy for locally advanced gastric cancer: FOCUS trial
1. This phase 3, randomized controlled trial demonstrated that S-1 plus oxaliplatin (SOX) was...
Read More
Capecitabine maintenance therapy for metastatic nasopharyngeal carcinoma improves progression-free survival
1. Progression-free survival is longer in those treated with capecitabine maintenance therapy as...
Read More
Abemaciclib linked to disease control in patients with p16ink4A-negative mesothelioma
1. Disease control was reported in over half of the patients treated with abemaciclib 2. Most...
Read More
Sintilimab plus anlotinib showed promising clinical and safety response to treat advanced cervical cancer
1. The overall response rate was 54.8% in the intention-to-treat group while it was 59.0% in the...
Read More
Axicabtagene ciloleucel improves event-free survival in relapsed or refractory large B-cell lymphoma
1. Patients with large B-cell lymphoma refractory to first-line therapy receiving axicabtagene...
Read More